Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer View Full Text


Ontology type: schema:ScholarlyArticle      Open Access: True


Article Info

DATE

2010-05

AUTHORS

Carlos H. Barrios, Mei-Ching Liu, Soo Chin Lee, Laurence Vanlemmens, Jean-Marc Ferrero, Toshio Tabei, Xavier Pivot, Hiroji Iwata, Kenjiro Aogi, Roberto Lugo-Quintana, Nadia Harbeck, Marla J. Brickman, Ke Zhang, Kenneth A. Kern, Miguel Martin

ABSTRACT

This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients with HER2-negative ABC that recurred after anthracycline and taxane therapy were randomized (1:1) to sunitinib 37.5 mg/day or capecitabine 1,250 mg/m(2) (1,000 mg/m(2) in patients >65 years) BID on days 1-14 q3w. The independent data-monitoring committee (DMC) determined during the first interim analysis (238 patients randomized to sunitinib, 244 to capecitabine) that the trial be terminated due to futility in reaching the primary endpoint. No statistical evidence supported the hypothesis that sunitinib improved PFS compared with capecitabine (one-sided P = 0.999). The data indicated that PFS was shorter with sunitinib than capecitabine (median 2.8 vs. 4.2 months, respectively; HR, 1.47; 95% CI, 1.16-1.87; two-sided P = 0.002). Median overall survival (15.3 vs. 24.6 months; HR, 1.17; two-sided P = 0.350) and objective response rates (11 vs. 16%; odds ratio, 0.65; P = 0.109) were numerically inferior with sunitinib versus capecitabine. While no new or unexpected safety findings were reported, sunitinib treatment was associated with higher frequencies and greater severities of many common adverse events (AEs) compared with capecitabine, resulting in more temporary discontinuations due to AEs with sunitinib (66 vs. 51%). The relative dose intensity was lower with sunitinib than capecitabine (73 vs. 95%). Based on these efficacy and safety results, sunitinib should not be used as monotherapy for patients with ABC. More... »

PAGES

121-131

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s10549-010-0788-0

DOI

http://dx.doi.org/10.1007/s10549-010-0788-0

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1027199206

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/20339913


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Antineoplastic Agents", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Breast Neoplasms", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Capecitabine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Deoxycytidine", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Disease-Free Survival", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Fluorouracil", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Genes, erbB-2", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Indoles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Kaplan-Meier Estimate", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Pyrroles", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Sunitinib", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Pontifical Catholic University of Rio Grande do Sul", 
          "id": "https://www.grid.ac/institutes/grid.412519.a", 
          "name": [
            "PUCRS School of Medicine, Centro de Pesquisa em Oncologia, Av. Ipiranga, 6690\u20144 andar, Jardim Botanico, 90610-000, Porto Alegre, RS, Brazil"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Barrios", 
        "givenName": "Carlos H.", 
        "id": "sg:person.01306217545.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306217545.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Koo Foundation Sun Yat-Sen Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.418962.0", 
          "name": [
            "Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, ROC"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Liu", 
        "givenName": "Mei-Ching", 
        "id": "sg:person.01053554560.36", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053554560.36"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "National University Health System", 
          "id": "https://www.grid.ac/institutes/grid.410759.e", 
          "name": [
            "National University Health System, Singapore, Singapore"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lee", 
        "givenName": "Soo Chin", 
        "id": "sg:person.012743725014.57", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012743725014.57"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Center Oscar Lambret, Lille, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Vanlemmens", 
        "givenName": "Laurence", 
        "id": "sg:person.01203421150.75", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203421150.75"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Center Antoine Lacassagne, Nice, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Ferrero", 
        "givenName": "Jean-Marc", 
        "id": "sg:person.01014626365.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014626365.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Saitama Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.416695.9", 
          "name": [
            "Saitama Cancer Center, Saitama, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Tabei", 
        "givenName": "Toshio", 
        "id": "sg:person.01270043644.88", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270043644.88"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Centre Hospitalier Universitaire de Besan\u00e7on", 
          "id": "https://www.grid.ac/institutes/grid.411158.8", 
          "name": [
            "H\u00f4pital Jean Minjoz, Besan\u00e7on, France"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Pivot", 
        "givenName": "Xavier", 
        "id": "sg:person.0717173510.96", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717173510.96"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Aichi Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.410800.d", 
          "name": [
            "Aichi Cancer Center Hospital, Nagoya, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Iwata", 
        "givenName": "Hiroji", 
        "id": "sg:person.013142720612.73", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013142720612.73"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Shikoku Cancer Center", 
          "id": "https://www.grid.ac/institutes/grid.415740.3", 
          "name": [
            "Shikoku Cancer Center, Ehime, Japan"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Aogi", 
        "givenName": "Kenjiro", 
        "id": "sg:person.01204564423.98", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204564423.98"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Hospital Christus Muguerza del Parque, Chihuauhua, Mexico"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Lugo-Quintana", 
        "givenName": "Roberto", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Technical University Munich", 
          "id": "https://www.grid.ac/institutes/grid.6936.a", 
          "name": [
            "University of Cologne, Cologne, Germany", 
            "Technische Universitaet Muenchen, Munchen, Germany"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Harbeck", 
        "givenName": "Nadia", 
        "id": "sg:person.0735450544.81", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735450544.81"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pfizer (United States)", 
          "id": "https://www.grid.ac/institutes/grid.410513.2", 
          "name": [
            "Pfizer Oncology, New York, NY, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Brickman", 
        "givenName": "Marla J.", 
        "id": "sg:person.01110070400.54", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110070400.54"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Oncology, La Jolla, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Zhang", 
        "givenName": "Ke", 
        "id": "sg:person.01052026125.28", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052026125.28"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "name": [
            "Pfizer Oncology, La Jolla, CA, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Kern", 
        "givenName": "Kenneth A.", 
        "id": "sg:person.01017132655.49", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017132655.49"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Hospital General Universitario Gregorio Mara\u00f1\u00f3n", 
          "id": "https://www.grid.ac/institutes/grid.410526.4", 
          "name": [
            "Hospital Universitario Gregorio Maranon, Madrid, Spain"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Martin", 
        "givenName": "Miguel", 
        "id": "sg:person.011007714002.18", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011007714002.18"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1097/cad.0b013e32832b2ea0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000694748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e32832b2ea0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000694748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e32832b2ea0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000694748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1097/cad.0b013e32832b2ea0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1000694748"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2008.20.5476", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1001930965"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/annonc/mdf101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017095708"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2353/ajpath.2009.081030", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018137780"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2007.14.5375", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1028322640"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.ejca.2009.02.011", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1029796782"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejm200103153441101", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031768583"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/jnci/92.3.205", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032301848"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2010.28.0982", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1032315475"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1056/nejmoa072113", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033842397"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1038/ncponc0905", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1036209952", 
          "https://doi.org/10.1038/ncponc0905"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1200/jco.2005.05.098", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1038129810"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1170-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042343030", 
          "https://doi.org/10.1007/s00280-009-1170-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1170-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042343030", 
          "https://doi.org/10.1007/s00280-009-1170-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00280-009-1170-y", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042343030", 
          "https://doi.org/10.1007/s00280-009-1170-y"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1017/s1470903106009357", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048474586"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1053/j.seminoncol.2003.08.013", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1048913834"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.sabcs-09-41", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063217258"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1158/0008-5472.sabcs-09-61", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1063217613"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075221300", 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://app.dimensions.ai/details/publication/pub.1075286502", 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2010-05", 
    "datePublishedReg": "2010-05-01", 
    "description": "This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients with HER2-negative ABC that recurred after anthracycline and taxane therapy were randomized (1:1) to sunitinib 37.5 mg/day or capecitabine 1,250 mg/m(2) (1,000 mg/m(2) in patients >65 years) BID on days 1-14 q3w. The independent data-monitoring committee (DMC) determined during the first interim analysis (238 patients randomized to sunitinib, 244 to capecitabine) that the trial be terminated due to futility in reaching the primary endpoint. No statistical evidence supported the hypothesis that sunitinib improved PFS compared with capecitabine (one-sided P = 0.999). The data indicated that PFS was shorter with sunitinib than capecitabine (median 2.8 vs. 4.2 months, respectively; HR, 1.47; 95% CI, 1.16-1.87; two-sided P = 0.002). Median overall survival (15.3 vs. 24.6 months; HR, 1.17; two-sided P = 0.350) and objective response rates (11 vs. 16%; odds ratio, 0.65; P = 0.109) were numerically inferior with sunitinib versus capecitabine. While no new or unexpected safety findings were reported, sunitinib treatment was associated with higher frequencies and greater severities of many common adverse events (AEs) compared with capecitabine, resulting in more temporary discontinuations due to AEs with sunitinib (66 vs. 51%). The relative dose intensity was lower with sunitinib than capecitabine (73 vs. 95%). Based on these efficacy and safety results, sunitinib should not be used as monotherapy for patients with ABC.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s10549-010-0788-0", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": true, 
    "isPartOf": [
      {
        "id": "sg:journal.1092777", 
        "issn": [
          "0167-6806", 
          "1573-7217"
        ], 
        "name": "Breast Cancer Research and Treatment", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "1", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "121"
      }
    ], 
    "name": "Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer", 
    "pagination": "121-131", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "8190aa0c47a881372613a04c2d0750a9caa2945fc8043078e1b422efbf19c2fe"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "20339913"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "8111104"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s10549-010-0788-0"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1027199206"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s10549-010-0788-0", 
      "https://app.dimensions.ai/details/publication/pub.1027199206"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T10:17", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000348_0000000348/records_54310_00000000.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "http://link.springer.com/10.1007/s10549-010-0788-0"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s10549-010-0788-0'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s10549-010-0788-0'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s10549-010-0788-0'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s10549-010-0788-0'


 

This table displays all metadata directly associated to this object as RDF triples.

313 TRIPLES      21 PREDICATES      61 URIs      34 LITERALS      22 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s10549-010-0788-0 schema:about N1209ad4714b4497d8520ea6033950656
2 N1f838294f1cd45ad9ae54c749f2df15d
3 N22024aff49564de3838d54f493bdbbe9
4 N308babf63a904ad2b68e966155e2ef4b
5 N3cd1d7404dfc4612a483ac8f86d380b4
6 N5a2ec99be88548b3a1abcbe2949968e3
7 N5fb6dde57219424bb2cf0d6a395a4ca0
8 N607b1b467ce644e68579bd2f5520795c
9 N634009d60b054d0ea89ede3132a903a3
10 N80ab808f45f844edb521b93167441d68
11 N81d336d615f5445b89adcd135489b29c
12 Nb4cf1c3430ff43028e33b142de246fa5
13 Nb8f11e8a8d174d6db59d6ec90066700c
14 anzsrc-for:11
15 anzsrc-for:1103
16 schema:author Nb02054355bfb4f61b8bd91a9efb196fe
17 schema:citation sg:pub.10.1007/s00280-009-1170-y
18 sg:pub.10.1038/ncponc0905
19 https://app.dimensions.ai/details/publication/pub.1075221300
20 https://app.dimensions.ai/details/publication/pub.1075286502
21 https://doi.org/10.1016/j.ejca.2009.02.011
22 https://doi.org/10.1017/s1470903106009357
23 https://doi.org/10.1053/j.seminoncol.2003.08.013
24 https://doi.org/10.1056/nejm200103153441101
25 https://doi.org/10.1056/nejmoa072113
26 https://doi.org/10.1093/annonc/mdf101
27 https://doi.org/10.1093/jnci/92.3.205
28 https://doi.org/10.1097/cad.0b013e32832b2ea0
29 https://doi.org/10.1158/0008-5472.sabcs-09-41
30 https://doi.org/10.1158/0008-5472.sabcs-09-61
31 https://doi.org/10.1200/jco.2005.05.098
32 https://doi.org/10.1200/jco.2007.14.5375
33 https://doi.org/10.1200/jco.2008.20.5476
34 https://doi.org/10.1200/jco.2010.28.0982
35 https://doi.org/10.2353/ajpath.2009.081030
36 schema:datePublished 2010-05
37 schema:datePublishedReg 2010-05-01
38 schema:description This multicenter, randomized, open-label phase III trial (planned enrollment: 700 patients) was conducted to test the hypothesis that single-agent sunitinib improves progression-free survival (PFS) compared with capecitabine as treatment for advanced breast cancer (ABC). Patients with HER2-negative ABC that recurred after anthracycline and taxane therapy were randomized (1:1) to sunitinib 37.5 mg/day or capecitabine 1,250 mg/m(2) (1,000 mg/m(2) in patients >65 years) BID on days 1-14 q3w. The independent data-monitoring committee (DMC) determined during the first interim analysis (238 patients randomized to sunitinib, 244 to capecitabine) that the trial be terminated due to futility in reaching the primary endpoint. No statistical evidence supported the hypothesis that sunitinib improved PFS compared with capecitabine (one-sided P = 0.999). The data indicated that PFS was shorter with sunitinib than capecitabine (median 2.8 vs. 4.2 months, respectively; HR, 1.47; 95% CI, 1.16-1.87; two-sided P = 0.002). Median overall survival (15.3 vs. 24.6 months; HR, 1.17; two-sided P = 0.350) and objective response rates (11 vs. 16%; odds ratio, 0.65; P = 0.109) were numerically inferior with sunitinib versus capecitabine. While no new or unexpected safety findings were reported, sunitinib treatment was associated with higher frequencies and greater severities of many common adverse events (AEs) compared with capecitabine, resulting in more temporary discontinuations due to AEs with sunitinib (66 vs. 51%). The relative dose intensity was lower with sunitinib than capecitabine (73 vs. 95%). Based on these efficacy and safety results, sunitinib should not be used as monotherapy for patients with ABC.
39 schema:genre research_article
40 schema:inLanguage en
41 schema:isAccessibleForFree true
42 schema:isPartOf N13356ede81c54370a39903220267aeb3
43 N4e6e0acc1dc6479ea6724b7f30cc45e8
44 sg:journal.1092777
45 schema:name Phase III randomized trial of sunitinib versus capecitabine in patients with previously treated HER2-negative advanced breast cancer
46 schema:pagination 121-131
47 schema:productId N0cc8ffbc327e4b229f674e751a3e9f9c
48 N20e664b820144e6fa4e47e7f67b998b0
49 N2e824dfd3e0a45fca3af24a6877ea434
50 N3cb9233c3d8941e68bd0050fd6de94c5
51 Nc194992e24b54299a289bfa3e4f02498
52 schema:sameAs https://app.dimensions.ai/details/publication/pub.1027199206
53 https://doi.org/10.1007/s10549-010-0788-0
54 schema:sdDatePublished 2019-04-11T10:17
55 schema:sdLicense https://scigraph.springernature.com/explorer/license/
56 schema:sdPublisher N4d20027eee51499bbc2cf06a04b3f2cc
57 schema:url http://link.springer.com/10.1007/s10549-010-0788-0
58 sgo:license sg:explorer/license/
59 sgo:sdDataset articles
60 rdf:type schema:ScholarlyArticle
61 N01a6c138cab141b9a74eec565bd67338 rdf:first sg:person.01204564423.98
62 rdf:rest N2e5d99674eb24e63a72a1f7872136ec4
63 N0cc8ffbc327e4b229f674e751a3e9f9c schema:name pubmed_id
64 schema:value 20339913
65 rdf:type schema:PropertyValue
66 N1209ad4714b4497d8520ea6033950656 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
67 schema:name Genes, erbB-2
68 rdf:type schema:DefinedTerm
69 N13356ede81c54370a39903220267aeb3 schema:volumeNumber 121
70 rdf:type schema:PublicationVolume
71 N1865609b76674bb398544a6b8769769d rdf:first sg:person.01014626365.81
72 rdf:rest N691336268fba431398d9883bcab4eedb
73 N1f838294f1cd45ad9ae54c749f2df15d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
74 schema:name Fluorouracil
75 rdf:type schema:DefinedTerm
76 N20e664b820144e6fa4e47e7f67b998b0 schema:name readcube_id
77 schema:value 8190aa0c47a881372613a04c2d0750a9caa2945fc8043078e1b422efbf19c2fe
78 rdf:type schema:PropertyValue
79 N22024aff49564de3838d54f493bdbbe9 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
80 schema:name Sunitinib
81 rdf:type schema:DefinedTerm
82 N2a0814a60e174caba953d46e12533427 rdf:first sg:person.01203421150.75
83 rdf:rest N1865609b76674bb398544a6b8769769d
84 N2c537844c88242ba8ef266e883804519 schema:name Hospital Christus Muguerza del Parque, Chihuauhua, Mexico
85 rdf:type schema:Organization
86 N2e5d99674eb24e63a72a1f7872136ec4 rdf:first Nefafd7d769734e42b45b07c347e97c25
87 rdf:rest Nfeea251b6a8a4550aa9ee932fa0d81c3
88 N2e824dfd3e0a45fca3af24a6877ea434 schema:name doi
89 schema:value 10.1007/s10549-010-0788-0
90 rdf:type schema:PropertyValue
91 N308babf63a904ad2b68e966155e2ef4b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
92 schema:name Disease-Free Survival
93 rdf:type schema:DefinedTerm
94 N3cb9233c3d8941e68bd0050fd6de94c5 schema:name dimensions_id
95 schema:value pub.1027199206
96 rdf:type schema:PropertyValue
97 N3cd1d7404dfc4612a483ac8f86d380b4 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
98 schema:name Pyrroles
99 rdf:type schema:DefinedTerm
100 N4ce4e66392a548d5b67a6915208aef57 rdf:first sg:person.01017132655.49
101 rdf:rest N535f05b490144f4f84f4b0a501a997a8
102 N4d20027eee51499bbc2cf06a04b3f2cc schema:name Springer Nature - SN SciGraph project
103 rdf:type schema:Organization
104 N4e6e0acc1dc6479ea6724b7f30cc45e8 schema:issueNumber 1
105 rdf:type schema:PublicationIssue
106 N535f05b490144f4f84f4b0a501a997a8 rdf:first sg:person.011007714002.18
107 rdf:rest rdf:nil
108 N5a2ec99be88548b3a1abcbe2949968e3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Kaplan-Meier Estimate
110 rdf:type schema:DefinedTerm
111 N5ab3f550678540b7a93a79fa5b875735 schema:name Center Oscar Lambret, Lille, France
112 rdf:type schema:Organization
113 N5fb6dde57219424bb2cf0d6a395a4ca0 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Capecitabine
115 rdf:type schema:DefinedTerm
116 N607b1b467ce644e68579bd2f5520795c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
117 schema:name Humans
118 rdf:type schema:DefinedTerm
119 N634009d60b054d0ea89ede3132a903a3 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
120 schema:name Antineoplastic Agents
121 rdf:type schema:DefinedTerm
122 N691336268fba431398d9883bcab4eedb rdf:first sg:person.01270043644.88
123 rdf:rest Nf8a6cb978b854a739221a8942cf0836d
124 N80ab808f45f844edb521b93167441d68 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
125 schema:name Deoxycytidine
126 rdf:type schema:DefinedTerm
127 N81d336d615f5445b89adcd135489b29c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
128 schema:name Breast Neoplasms
129 rdf:type schema:DefinedTerm
130 Na80fb054a50543e1953eafeca27f1720 rdf:first sg:person.01052026125.28
131 rdf:rest N4ce4e66392a548d5b67a6915208aef57
132 Nb02054355bfb4f61b8bd91a9efb196fe rdf:first sg:person.01306217545.49
133 rdf:rest Nbd7fce1c0624483db2ab7afedb8bb604
134 Nb1d9841ed2f54021a7ba96511317ded1 rdf:first sg:person.01110070400.54
135 rdf:rest Na80fb054a50543e1953eafeca27f1720
136 Nb321e812f1844a579bda5f6b29d9786b rdf:first sg:person.012743725014.57
137 rdf:rest N2a0814a60e174caba953d46e12533427
138 Nb4cf1c3430ff43028e33b142de246fa5 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
139 schema:name Indoles
140 rdf:type schema:DefinedTerm
141 Nb66a4ead24204f14afeb66271ed9867c schema:name Pfizer Oncology, La Jolla, CA, USA
142 rdf:type schema:Organization
143 Nb8f11e8a8d174d6db59d6ec90066700c schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Female
145 rdf:type schema:DefinedTerm
146 Nbd7fce1c0624483db2ab7afedb8bb604 rdf:first sg:person.01053554560.36
147 rdf:rest Nb321e812f1844a579bda5f6b29d9786b
148 Nc194992e24b54299a289bfa3e4f02498 schema:name nlm_unique_id
149 schema:value 8111104
150 rdf:type schema:PropertyValue
151 Nc38dfd2651c6417aa65b79b91830eb70 schema:name Pfizer Oncology, La Jolla, CA, USA
152 rdf:type schema:Organization
153 Nd1a479c90949463abc98e9c438ff4ab9 schema:name Center Antoine Lacassagne, Nice, France
154 rdf:type schema:Organization
155 Ne756d7fe5abe44059b1e6c2be7ecf4c0 rdf:first sg:person.013142720612.73
156 rdf:rest N01a6c138cab141b9a74eec565bd67338
157 Nefafd7d769734e42b45b07c347e97c25 schema:affiliation N2c537844c88242ba8ef266e883804519
158 schema:familyName Lugo-Quintana
159 schema:givenName Roberto
160 rdf:type schema:Person
161 Nf8a6cb978b854a739221a8942cf0836d rdf:first sg:person.0717173510.96
162 rdf:rest Ne756d7fe5abe44059b1e6c2be7ecf4c0
163 Nfeea251b6a8a4550aa9ee932fa0d81c3 rdf:first sg:person.0735450544.81
164 rdf:rest Nb1d9841ed2f54021a7ba96511317ded1
165 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
166 schema:name Medical and Health Sciences
167 rdf:type schema:DefinedTerm
168 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
169 schema:name Clinical Sciences
170 rdf:type schema:DefinedTerm
171 sg:journal.1092777 schema:issn 0167-6806
172 1573-7217
173 schema:name Breast Cancer Research and Treatment
174 rdf:type schema:Periodical
175 sg:person.01014626365.81 schema:affiliation Nd1a479c90949463abc98e9c438ff4ab9
176 schema:familyName Ferrero
177 schema:givenName Jean-Marc
178 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01014626365.81
179 rdf:type schema:Person
180 sg:person.01017132655.49 schema:affiliation Nb66a4ead24204f14afeb66271ed9867c
181 schema:familyName Kern
182 schema:givenName Kenneth A.
183 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01017132655.49
184 rdf:type schema:Person
185 sg:person.01052026125.28 schema:affiliation Nc38dfd2651c6417aa65b79b91830eb70
186 schema:familyName Zhang
187 schema:givenName Ke
188 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01052026125.28
189 rdf:type schema:Person
190 sg:person.01053554560.36 schema:affiliation https://www.grid.ac/institutes/grid.418962.0
191 schema:familyName Liu
192 schema:givenName Mei-Ching
193 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01053554560.36
194 rdf:type schema:Person
195 sg:person.011007714002.18 schema:affiliation https://www.grid.ac/institutes/grid.410526.4
196 schema:familyName Martin
197 schema:givenName Miguel
198 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.011007714002.18
199 rdf:type schema:Person
200 sg:person.01110070400.54 schema:affiliation https://www.grid.ac/institutes/grid.410513.2
201 schema:familyName Brickman
202 schema:givenName Marla J.
203 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01110070400.54
204 rdf:type schema:Person
205 sg:person.01203421150.75 schema:affiliation N5ab3f550678540b7a93a79fa5b875735
206 schema:familyName Vanlemmens
207 schema:givenName Laurence
208 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01203421150.75
209 rdf:type schema:Person
210 sg:person.01204564423.98 schema:affiliation https://www.grid.ac/institutes/grid.415740.3
211 schema:familyName Aogi
212 schema:givenName Kenjiro
213 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01204564423.98
214 rdf:type schema:Person
215 sg:person.01270043644.88 schema:affiliation https://www.grid.ac/institutes/grid.416695.9
216 schema:familyName Tabei
217 schema:givenName Toshio
218 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01270043644.88
219 rdf:type schema:Person
220 sg:person.012743725014.57 schema:affiliation https://www.grid.ac/institutes/grid.410759.e
221 schema:familyName Lee
222 schema:givenName Soo Chin
223 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.012743725014.57
224 rdf:type schema:Person
225 sg:person.01306217545.49 schema:affiliation https://www.grid.ac/institutes/grid.412519.a
226 schema:familyName Barrios
227 schema:givenName Carlos H.
228 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01306217545.49
229 rdf:type schema:Person
230 sg:person.013142720612.73 schema:affiliation https://www.grid.ac/institutes/grid.410800.d
231 schema:familyName Iwata
232 schema:givenName Hiroji
233 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.013142720612.73
234 rdf:type schema:Person
235 sg:person.0717173510.96 schema:affiliation https://www.grid.ac/institutes/grid.411158.8
236 schema:familyName Pivot
237 schema:givenName Xavier
238 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0717173510.96
239 rdf:type schema:Person
240 sg:person.0735450544.81 schema:affiliation https://www.grid.ac/institutes/grid.6936.a
241 schema:familyName Harbeck
242 schema:givenName Nadia
243 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0735450544.81
244 rdf:type schema:Person
245 sg:pub.10.1007/s00280-009-1170-y schema:sameAs https://app.dimensions.ai/details/publication/pub.1042343030
246 https://doi.org/10.1007/s00280-009-1170-y
247 rdf:type schema:CreativeWork
248 sg:pub.10.1038/ncponc0905 schema:sameAs https://app.dimensions.ai/details/publication/pub.1036209952
249 https://doi.org/10.1038/ncponc0905
250 rdf:type schema:CreativeWork
251 https://app.dimensions.ai/details/publication/pub.1075221300 schema:CreativeWork
252 https://app.dimensions.ai/details/publication/pub.1075286502 schema:CreativeWork
253 https://doi.org/10.1016/j.ejca.2009.02.011 schema:sameAs https://app.dimensions.ai/details/publication/pub.1029796782
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1017/s1470903106009357 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048474586
256 rdf:type schema:CreativeWork
257 https://doi.org/10.1053/j.seminoncol.2003.08.013 schema:sameAs https://app.dimensions.ai/details/publication/pub.1048913834
258 rdf:type schema:CreativeWork
259 https://doi.org/10.1056/nejm200103153441101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031768583
260 rdf:type schema:CreativeWork
261 https://doi.org/10.1056/nejmoa072113 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033842397
262 rdf:type schema:CreativeWork
263 https://doi.org/10.1093/annonc/mdf101 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017095708
264 rdf:type schema:CreativeWork
265 https://doi.org/10.1093/jnci/92.3.205 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032301848
266 rdf:type schema:CreativeWork
267 https://doi.org/10.1097/cad.0b013e32832b2ea0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1000694748
268 rdf:type schema:CreativeWork
269 https://doi.org/10.1158/0008-5472.sabcs-09-41 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063217258
270 rdf:type schema:CreativeWork
271 https://doi.org/10.1158/0008-5472.sabcs-09-61 schema:sameAs https://app.dimensions.ai/details/publication/pub.1063217613
272 rdf:type schema:CreativeWork
273 https://doi.org/10.1200/jco.2005.05.098 schema:sameAs https://app.dimensions.ai/details/publication/pub.1038129810
274 rdf:type schema:CreativeWork
275 https://doi.org/10.1200/jco.2007.14.5375 schema:sameAs https://app.dimensions.ai/details/publication/pub.1028322640
276 rdf:type schema:CreativeWork
277 https://doi.org/10.1200/jco.2008.20.5476 schema:sameAs https://app.dimensions.ai/details/publication/pub.1001930965
278 rdf:type schema:CreativeWork
279 https://doi.org/10.1200/jco.2010.28.0982 schema:sameAs https://app.dimensions.ai/details/publication/pub.1032315475
280 rdf:type schema:CreativeWork
281 https://doi.org/10.2353/ajpath.2009.081030 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018137780
282 rdf:type schema:CreativeWork
283 https://www.grid.ac/institutes/grid.410513.2 schema:alternateName Pfizer (United States)
284 schema:name Pfizer Oncology, New York, NY, USA
285 rdf:type schema:Organization
286 https://www.grid.ac/institutes/grid.410526.4 schema:alternateName Hospital General Universitario Gregorio Marañón
287 schema:name Hospital Universitario Gregorio Maranon, Madrid, Spain
288 rdf:type schema:Organization
289 https://www.grid.ac/institutes/grid.410759.e schema:alternateName National University Health System
290 schema:name National University Health System, Singapore, Singapore
291 rdf:type schema:Organization
292 https://www.grid.ac/institutes/grid.410800.d schema:alternateName Aichi Cancer Center
293 schema:name Aichi Cancer Center Hospital, Nagoya, Japan
294 rdf:type schema:Organization
295 https://www.grid.ac/institutes/grid.411158.8 schema:alternateName Centre Hospitalier Universitaire de Besançon
296 schema:name Hôpital Jean Minjoz, Besançon, France
297 rdf:type schema:Organization
298 https://www.grid.ac/institutes/grid.412519.a schema:alternateName Pontifical Catholic University of Rio Grande do Sul
299 schema:name PUCRS School of Medicine, Centro de Pesquisa em Oncologia, Av. Ipiranga, 6690—4 andar, Jardim Botanico, 90610-000, Porto Alegre, RS, Brazil
300 rdf:type schema:Organization
301 https://www.grid.ac/institutes/grid.415740.3 schema:alternateName Shikoku Cancer Center
302 schema:name Shikoku Cancer Center, Ehime, Japan
303 rdf:type schema:Organization
304 https://www.grid.ac/institutes/grid.416695.9 schema:alternateName Saitama Cancer Center
305 schema:name Saitama Cancer Center, Saitama, Japan
306 rdf:type schema:Organization
307 https://www.grid.ac/institutes/grid.418962.0 schema:alternateName Koo Foundation Sun Yat-Sen Cancer Center
308 schema:name Koo Foundation Sun Yat-Sen Cancer Center, Taipei, Taiwan, ROC
309 rdf:type schema:Organization
310 https://www.grid.ac/institutes/grid.6936.a schema:alternateName Technical University Munich
311 schema:name Technische Universitaet Muenchen, Munchen, Germany
312 University of Cologne, Cologne, Germany
313 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...